Open Orphan

Shareholders approve Venn Life Sciences PLC / Open Orphan merger

Cathal Friel, chief executive of Venn Life Sciences Holdings plc (LON:VENN) and founder of Open Orphan spoke to Proactive London's Andrew Scott following a general meeting to approve the merger of the two companies.

Friel, a co-founder of Amryt Pharma PLC (LON:AMYT), former chairman of Fastnet Oil & Gas for five years, and now chief executive of Venn, set up Open Orphan two years ago.

He and his team want to grow the company into a full-service consultancy for orphan and rare disease drugs.

Quick facts: Open Orphan

Price: £0.06

Market: AIM
Market Cap: £16.11 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan named herein, including the promotion by the Company of Open Orphan in any Content on the Site, the Company receives from said...



Venn Life CEO Richardson comments on Kinesis deal

Tony Richardson, chief executive Venn Life Sciences (LON:VENN), says the company’s acquisition of Dutch drug consultancy Kinesis allows it to pair early and late-stage drug development together. Venn currently offers clinical trial management, monitoring and biometric data services to...

on 09/22/2015

2 min read